Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in moderately to severely active ulcerative colitis
NCT06588855Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Afimkibart with Placebo (2 arms). Primary endpoint: Percentage of Participants with Clinical Remission at 12 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06588855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588855.